# Zhimeng Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhimeng-biopharma

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.core-biopharma.com
- Total disclosed funding: $90M
- Latest round: Series B (Nov 8, 2021)
- Investors on record: 16

## About

Established in 2017 and based in Shanghai, China, Zhimeng Biopharma is a medicines' developer that focuses on chronic hepatitis B. In November 2021, the firm raised CNY 350 million in series B funding. Huanming Chen, the company's co-founder, president and CEO, previously served as vice president of Shanghai Medicilon Biotech Co., Ltd. and senior pharmaceutical R&D director of BioDuro Technologies (Beijing) Co., Ltd.

The company's main products include anti-hepatitis B virus (HBV) drugs. Anti-hepatitis B virus (HBV) drugs include HBV nucleocapsid inhibitors, HBV RNA destabilizers and TLR8 agonists.

The company’s revenue is generated by providing anti-hepatitis B virus (HBV) drugs.

The company will use the funding for Phase II clinical studies of ZM-H1505R, a hepatitis B virus nucleocapsid inhibitor, and Phase I clinical studies of immunomodulators for the treatment of hepatitis B and KCNQ2/3 potassium channel openers for the treatment of epilepsy, pain, and depression.

## Funding rounds

- Series B, Nov 8, 2021, $55M — Fortune Capital, CoStone Capital, Advantech Capital, DYEE Capital, China Fellow Partners, Dawu Venture
- Series A, Nov 6, 2020, $35M — South China Venture Capital, Photon Fund, Shenzhen Capital Real Estate Fund, Lake Ventures, SDIC Unity Capital, Oceanpine Capital, Trinity Innovation Fund
- Angel, Feb 5, 2018 — Legend Star, Suzhou TechWisdom Capital, Bohe Angel Fund

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Angel
- Suzhou TechWisdom Capital — Angel
- Bohe Angel Fund — Angel
- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series A
- Photon Fund (https://capitalatlas.ai/funds/photon-fund) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Lake Ventures — Series A
- SDIC Unity Capital (https://capitalatlas.ai/funds/sdic-unity-capital) — Series A
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series A
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A
- Fortune Capital — Series B
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series B
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series B
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series B
- China Fellow Partners (https://capitalatlas.ai/funds/china-fellow-partners) — Series B
- Dawu Venture — Series B